What question did this study set out to answer?

The study investigates the viability of anti-parasitic drugs ivermectin and fenbendazole as potential therapeutic agents in ovarian cancer.

Evaluation of Anti-Parasitic Agents Ivermectin and Fenbendazole in Ovarian Cancer

View Full Paper

Ask AI

Bookmark

Authors

This evaluation reveals the anti-cancer potential of two anti-parasitic drugs in ovarian cancer, suggesting new treatment possibilities.

The study investigates the viability of anti-parasitic drugs ivermectin and fenbendazole as potential therapeutic agents in ovarian cancer.
Screened ivermectin and fenbendazole on ovarian cancer cell lines SKOV3 and ES-2.
Employed a luminescence-based CellTiter-Glo cell viability assay.
Analyzed correlation between MYC gene expression and survival rates using The Cancer Genomic Atlas.
Both drugs exhibited varying anti-proliferative effects on SKOV3 and ES-2 cell lines.
ES-2 cells showed a clear dose-dependent decrease in viability after treatment with both drugs.
IC50 values indicated fenbendazole had a lower IC50 in SKOV3 than ivermectin, while both drugs had similar IC50 values in ES-2.

Negrete et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark